Special Issue "Current Advances in Solid Tumor Mechanisms, Prognoses, or Personalized Treatments"
Deadline for manuscript submissions: 15 October 2023 | Viewed by 1386
2. Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei 230022, China
Interests: tumor molecular subtyping; tumor immunotherapy; mice model; multiomics analysis; solid tumor prognosis
Solid tumors account for approximately 90 percent of adult cancers. They can appear in a variety of locations across the human body, including in the breast, lung, prostate, colon, melanoma, bladder, and kidney. Solid tumors are heterotypic aggregates of many cell types, including cancer cells, cancer stem cells, connective tissue cells, and immune cells. Therefore, solid tumors are heterogeneous among different patients, which is linked with the diverse activated signaling pathways as well as genetic alterations, resulting in prognoses or medicine resistance.
In recent years, technological breakthroughs in the multiomics era, the wide application of transcriptomics, epigenomics, metabolomics, proteomics, and microbiomics, can deeply dig out the inner characteristics of each type of tumor; even those of each patient. These novel technical approaches, as well as algorithms that integrate different omics data types, can accelerate the identification of molecular patterns associated with solid tumors and guide clinical precision therapy.
We are pleased to invite you to submit papers with results that achieve novel insights into solid tumors, including, but not limited to, their mechanisms, prognoses, or personalized treatments. Articles concerning methods such as multiomics, single-cell, or in vivo experiments are welcome to the current Special Issue.
Dr. Jialin Meng
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- tumor molecular subtyping
- tumor microenvironment
- tumor mechanism
- clinical cohort
- machine learning
- single-cell sequence
- omics data
- prognosis signature
- personalized treatment